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Abstract
Warfarin has a long history of benefit and has become the gold standard medication for the prevention of
ischemic stroke in patients with atrial fibrillation. Nevertheless, it is far from perfect and there is no doubt that new
drugs must be found to replace warfarin. The new oral anticoagulants that are on the market or awaiting approval
or under research offer some benefits but not enough to replace warfarin until results of additional studies can
show an adequate balance between effectiveness/safety and cost/benefit. There are several issues concerning the
new oral anticoagulants. It is essential that the effect of any anticoagulant can be measured in plasma. But to date,
there is no test to assess the effect or therapeutic range for the new oral anticoagulants. There is no antidote to
neutralize the action of the new drugs in cases of bleeding or when acute surgical intervention is necessary.
Dabigatran requires dose adjustment in patients with moderate renal impairment and is contraindicated in patients
with severe renal failure. Rivaroxaban should be used with caution in patients with severe renal impairment.
Apixaban excretion is also partly dependent on renal function, although the impact of renal insufficiency has not
yet been determined. How anticoagulant bridging can be done before surgery has not yet been established. In
conclusion, although thousands of patients have been treated in phase III studies, additional data are necessary
before conclusions can be drawn on the potential for these new anticoagulant drugs to replace warfarin in
patients with atrial fibrillation.
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Introduction
Atrial fibrillation (AF) is the most common arrhythmia.
AF can present with significant symptoms or with just a
few cardiodynamic modifications that the patient is not
aware of. Its most feared complication is embolization
especially in the central nervous system. Each year, in
the United States alone, AF causes more than 50,000
strokes [1]. US statistics show there are currently more
than 2.3 million people with AF. This number is
expected to reach 6 million by 2050 in the United
States. Without adequate prophylactic and therapeutic
measures, morbidity and mortality from thromboembo-
lism will also increase in the future [2].
The pathophysiology of thrombosis indicates that
under conditions of high blood flow, the participation of
platelets in the initiation of a thrombus is the most
important target for inhibitors of platelet function used
as primary therapy. In the case of medium flow, anticoa-
gulant drugs seem to be a more appropriate therapy. A
combination of both strategies should not be ruled out
to provide better prevention than each individual ther-
apy. But during combined therapy, the potential benefits
could be distorted by adverse effects caused by increased
bleeding. Any antithrombotic drug or drug combination
with a higher level of prevention is certainly potentially
more hemorrhagic. This could be called the golden rule
in antithrombotic therapy.
The standard therapy available for thromboembolic
prevention in patients with AF is warfarin and in
patients with low risk according to the CHADS2 scale,
aspirin or no pharmacological therapy. Anticoagulant
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control therapy due to difficulty in maintaining adequate
international normalized ratio (INR) values (2.0-3.0),
reluctance of patients to undergo frequent blood tests,
or due to the risk factors that predispose to bleeding,
etc. The reality is that only 50-60% of patients with AF
who are suitable for anticoagulant therapy receive it pre-
ventively [3].
Recently, new antithrombotic drugs have become
available or are in phase III of clinical research, and
after more than 50 years will compete with warfarin in
the field of AF prevention. Warfarin has been, without
doubt, the gold standard medication for the prevention
of ischemic stroke but there are several reasons why this
medication is far from perfect. On the one hand, it has
the benefit of a well-established efficacy, there is a speci-
fic antidote in case of bleeding and the need to discon-
tinue the medication in an urgent situation, it has no
side effects and is not expensive. On the other hand,
warfarin has several disadvantages. Frequent monitoring
is required to maintain the INR between 2.0 and 3.0
which, even in the best hands, is achieved in 55-60% of
patients. It is necessary to have specialized clinics and
the therapeutic window is narrow. Warfarin has many
interactions with food and medicine, has a long half-life
and a very slow onset of action, and its pharmacokinetic
profile is affected by genetic polymorphisms that make
patients respond inadequately to medication. Moreover,
although the prothrombin time assay is a simple test,
INR (the test of choice for controlling warfarin) standar-
dization outside specialized laboratories is difficult. Dur-
ing surgery or other procedures, interruption of
treatment requires therapeutic tactics in skilled hands.
There are patients who need not be subjected to antic-
oagulation. How can they be identified? If anticoagulation
is unavoidable, which patientsw i l lb e n e f i t ?T h ec o n s e n -
sus of the European Society of Cardiology recommended
using the CHADS2 risk score; when it is 0, no medication
or aspirin is indicated. When the risk score is 1, the use
of aspirin or warfarin is appropriate and medical criteria
will define which one. When the risk score is ≥2, oral
anticoagulation is indicated. The CHA2D2-VASc scale
[4] adds additional risk factors that may be useful espe-
cially in patients with a risk score of one to decide
between the use of anticoagulants or aspirin.
The most severe complication that can arise from the
use of anticoagulants is bleeding. It should be empha-
sized that not only severe hemorrhage that affects the
brain, kidneys, or gastrointestinal tract is important.
When minor bleeding occurs, medication is stopped,
placing the patient in a potentially prothrombotic state.
It must accepted that any drug that has a higher level
of prevention will have potentially higher hemorrhagic
risk; this clinical problem is still unresolved. Therefore it
is essential that the effect of any anticoagulant medica-
tion can be measured in plasma, as done by prothrom-
bin time for warfarin control, activated partial
prothrombin time for administration of regular unfrac-
tionated heparin or the assay for plasma levels of anti-
activated factor X in the case of low molecular weight
heparins to avoid excessive or deficient anticoagulation
predisposing to hemorrhagic or thrombotic accidents.
Among the potential new therapies a warfarin-related
drug, tecarfarin [5], a vitamin K antagonist similar to
warfarin, has been studied. It is a vitamin K epoxide
reductase inhibitor which decreases the activity of vita-
min K-dependent coagulation factors (factors II, VII, IX,
and X) and prolongs the prothrombin time [6]. The
advantage is that it is metabolized through an esterase,
is not metabolized by cytochrome P450 [5] and avoids
the many interactions with food and medicine of war-
farin. Its control can also be monitored by the pro-
thrombin time and expressed as the INR, which seems
to remain more stable than with warfarin. The first
study was published in Circulation 2 years ago [7] on a
group of 66 patients, and more trials can be expected to
identify further benefits compared with warfarin and
other oral anticoagulants. Having a specific antidote and
am o r es t a b l ea c t i o nc o m p a r e dw i t hw a r f a r i ng i v e s
tecarfarin an interesting profile for the prevention of
thromboembolic diseases.
Analysis of antithrombotic strategies in AF
Oral anticoagulants and antiplatelet drugs
Before discussing studies on thromboembolic prevention
in AF, it must be borne in mind that patients seen in
daily clinical practice (the real world) often do not fit
the profile of those included in clinical trials.
Patients with AF have a 5-fold higher incidence of
ischemic brain injury and increased mortality. For sev-
eral decades, warfarin has been shown to be the medica-
tion of choice for the prevention of thromboembolism
in these patients. In 1994 a group of 3691 patients
included in 5 studies with and without treatment with
warfarin showed 68% risk reduction obtained by antic-
oagulant therapy, with virtually no increased risk of
bleeding [8]. Pooled analysis of patient-level data from
six published randomized clinical trials comparing
aspirin with warfarin showed that warfarin significantly
reduced the rate of ischemic stroke compared with
aspirin [9]. Also in 2007, a meta-analysis from 29 trials
that included 28,044 participants showed that warfarin
improved outcomes by 40% compared with antiplatelet
therapy in patients with AF [10].
Warfarin was found to be more protective than aspirin
even though those studies did not take into account risk
levels [11], but benefit was obtained even in patients
older than 75 years (mean 81.5 years) [12].
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in cardiology, it has been suggested that warfarin can be
replaced with the combined use of aspirin + clopidogrel.
We consider this possibility rational as we reported that
this antiplatelet drug combination lowered the amount
of thrombin formed in a system in vitro [13].
The ACTIVE study compares aspirin + clopidogrel
with warfarin and clopidogrel + aspirin with aspirin
alone [14]. The results (Table 1) indicate that warfarin
is superior to the combination of clopidogrel + aspirin
in the prevention of vascular events (P = 0.0002; num-
ber need to treat [NNT] = 50) with no increased inci-
dence of major bleeding (P = 0.67; number need to
harm [NNH] = 476).
Moreover, the use of clopidogrel associated with
aspirin (study Active A) prevented more thromboem-
bolic events than aspirin alone but at the expense of a
significant increase in major bleeding, and with a ten-
dency to increased mortality. As clopidogrel plus aspirin
reduces the risk of major vascular events, this combina-
tion is indicated when treatment with warfarin is diffi-
cult because patients refuse to be monitored or where
controls cannot be done or are not reliable. In this
regard, the possibility of resistance to clopidogrel and/or
aspirin [15,16] should be investigated.
In the AVERROES study [17], apixaban, an oral direct
inhibitor of activated factor X in doses of 5 mg twice
per day, was compared with aspirin. In this study, apixa-
ban was administered to 5600 patients with AF who had
relatively low risk (level 1-2 as measured by the
CHADS2 scale) and could not be medicated with war-
farin. Apixaban was compared with aspirin 81-324 mg/
day. The study was stopped ahead of schedule due to
the benefit seen in patients with apixaban. The reduc-
tion of ischemic stroke was statistically significant (P <
0.001) without increasing major bleeding complications
and a slight increase in minor bleeding (NNT = 91),
Warfarin and the new oral anticoagulants
Table 2 shows some pharmacodynamic characteristics of
the newer antithrombotic compounds compared with
warfarin. Of the new medication, only dabigatran has
been approved for use in AF. The other drugs are in
phase III studies. Trials designed to compare the new
agents with warfarin (Table 3) and based on the
criterion of noninferiority, have shown a significant
effect in the prevention of thromboembolic complica-
t i o n si np a t i e n t su n d e r g o i n g orthopedic surgery. Will
these new anticoagulants have a real impact on throm-
boembolic prevention, especially stroke, in patients with
AF? After presenting comparative studies in the follow-
ing paragraphs, the advantages and disadvantages in
relation to warfarin are discussed.
Dabigatran etexilate is a prodrug that becomes the
active principle dabigatran with specific inhibiting effects
of thrombin both free and bound to fibrin. In the RE-LY
study (Randomized Evaluation of Long-term anticoagu-
lant therapY) [18,19] dabigatran was administered in
two dosages: 150 mg or 110 mg twice daily. The results
based on the criterion of noninferiority indicate that the
dosage of 150 mg twice a day was significantly more
effective than warfarin in the prevention of ischemic
stroke with similar frequency of hemorrhagic stroke.
T h ed o s a g eo f1 1 0m gt w i c ead a yw a ss i m i l a rt ow a r -
farin in the prevention of thromboembolism and pre-
sented with lower hemorrhagic events. Patients treated
with a dosage of 150 mg twice daily had a 35% reduc-
tion in systemic embolism and 74% of the risk of
hemorrhagic stroke. These numbers are impressive.
The NNT can describe results from the perspective of
daily medical practice (Table 4). Although the differ-
ences between dabigatran and warfarin in some of the
outcomes are significant and related to the number of
patients included (6000 per group), the NNT of the end
points are unconvincing and the 35% reduction in
stroke does not seem as impressive. Results from phase
IV studies would provide more data on efficacy and
safety ratios.
When the side effects are considered (see below), it is
perhaps still premature to advocate this medication. For
example, the end points do not take into account minor
bleeding, which, although it does not complicate the
clinical evolution of patients, can result in the suspen-
sion of medication and a transient prothrombotic state.
Moreover, patients in the dabigatran group discontinued
the medication in larger numbers than those with war-
farin, because of gastrointestinal symptoms. Myocardial
infarction was also was more common in patients trea-
ted with dabigatran [19].
In certain circumstances (e.g., in patients with AF and
with coronary stent), the triple combination of aspirin,
clopidogrel and oral anticoagulants is required. Oldgren
et al. [20] compared triple therapy with dabigatran in
patients with recent myocardial infarction. Their study
showed that 3.8% of patients taking placebo died or had
a heart attack or stroke compared with dabigatran at
different doses, twice daily; 4.6% in those treated with
50 mg, 4.9% for 75 mg; 3.0% for 110 mg and 3.5% for
150 mg. Hemorrhages (major or clinically relevant
Table 1 Active W Study: outcomes
Outcomes Clopidogrel +
aspirin
Warfarin NNT or
NNH
P
Vascular events
(%/year)
5.64 3.63 50 0.0002
Major bleeding
(%/year)
2.42 2.21 476 0.67
NNH, number needed to harm; NNT, number needed to treat.
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increased dose-dependently with dabigatran: the hazard
ratio was 1.77 for 50 mg, 2.17 for 75 mg, 3.92 for 110
mg, and 4.27 for 150 mg compared with placebo.
It is interesting that the US Food and Drug Adminis-
tration (FDA) approved the 150 mg twice daily dosage
but not the lower dose and instead approved a 75 mg
twice daily dosage for patients with renal insufficiency
with creatinine clearance less than 30 mL/min. This is
supported by the Oasis 6 study [21], in which a statisti-
cally significant increase in bleeding was observed in
patients with creatinine clearance ≤30 mL/min when
using enoxaparin.
To investigate 110 mg dose, Eikelboom et al. [22]
compared hemorrhagic stroke in patients from the RE-
LY study who were older and younger than 75 years
and found that both doses of dabigatran have lower
risks of both intracranial and extracranial bleeding in
patients aged <75 years compared with warfarin. In
those aged ≥75 years, intracranial bleeding risk was
lower but extracranial bleeding risk was similar or
higher with both doses of dabigatran compared with
warfarin. This means that the positive balance of dabiga-
tran is less evident in older patients. The safety advan-
tages of dabigatran compared with warfarin are less
evident with increasing age.
Rivaroxaban is a new oral anticoagulant drug that acts
by inhibiting activated factor X. The Rocket-AF study
[23] compared rivaroxaban with warfarin in patients with
AF. It included more than 14,000 patients in a noninfer-
iority designed trial. Rivaroxaban dosage was 15-20 mg/
day and warfarin planned to maintain an INR of 2.0-3.0.
The primary end point was a reduction in embolic events
and evaluation of bleeding complications.
T h es a m ec r i t e r i aa sf o rd a b i g a t r a nc a nb ea p p l i e d
with regard to the NNT (Tables 5 and 6). For some
primary outcomes where the difference with warfarin is
significant P < 0.001), at least 192 patients must be trea-
ted in daily practice to prevent 1 case of vascular death,
stroke, or embolism.
The study results showed that rivaroxaban signifi-
cantly reduced intracranial bleeding compared with war-
farin. With regard this safety point, between 278 and
417 patients must be treated to obtain 1 case of reduc-
tion in critical organ bleeding or bleeding causing death
or intracranial hemorrhage in favor of rivaroxaban.
The MAGELLAN study [24] (data from A. Cohen pre-
sented at the American College of Cardiology Scientific
Sessions 2011) is an approach on security in nonsurgical
patients and serves to maintain alert about the hemor-
rhagic possibilities. Eight thousand one hundred and
one patients were randomized to 10 mg rivaroxaban
once daily for 35 days or standard treatment with sub-
cutaneous enoxaparin 40 mg once a day for 10 days.
The results of the MAGELLAN study show that when
rivaroxaban was administered for 35 days to prevent
deep venous thrombosis (composite efficacy outcomes
at day 10; 2.7%), there were no differences between riv-
aroxaban and enoxaparin; at day 35, NNT = 76.9 (rivar-
oxaban 4.4% enoxaparin 5.7%) with the following
increased bleeding complications: clinical relevant bleed-
ing at day 1-10 NNH = 62.5 (rivaroxaban 2.8%, enoxa-
parin 1.2%); at day 11-35 NNH = 111 (rivaroxaban 1.4%,
enoxaparin 0.5%). The rational question is whether
these results can be assimilated to what might happen
in patients with AF who are under treatment for much
longer periods. This requires taking into account certain
characteristics of the MAGELLAN study (the compari-
son was made with enoxaparin; the clinical patients
apparently had more severe disease and high mortality
rate), but nevertheless this indicates again that a fixed
Table 2 Characteristics of new oral anticoagulants compared with warfarin
Agent Main action Half-life
(h)
Renal clearance
(%)
Cross
placenta
Dose Interactions
Rivaroxaban Anti-factor Xa 6-10 66 + Once daily CYP3A4 inhibitors
Apixaban Anti-factor Xa 10-15 30 + Twice daily CYP3A4 inhibitors
Dabigatran Anti-factor IIa 12-14 80 + Twice daily PPIs
Warfarin Synthesis of vitamin K-dependent
factors
36-50 + Adjusted by INR, once
daily
Multiple with food and
drugs
PPIs, proton pump inhibitors. Quinidine is contraindicated for patients on dabigatran. Amiodarone or rifampicin require caution.
Table 3 Trials designed to compare the new oral anticoagulants to prevent thromboembolism with warfarin in AF
Trial Study drug Dosing Number of patients Design
RE-LY Dabigatran 110 mg twice daily, 150 mg twice daily 18,113 Randomized, open-label, noninferiority
Rocket-AF Rivaroxaban 15 mg daily, 20 mg daily 14,000 Randomized, double blind, noninferiority
ARISTOTLE Apixaban 5 mg twice daily 15,000 Randomized, double blind, noninferiority
Engage AF Edoxaban 30 mg daily, 60 mg daily 16,500 Randomized, double blind, noninferiority
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ance in efficacy/safety for new antithrombotics.
Apixaban, another direct inhibitor of activated factor
X, was also used to assess benefit in patients with AF
[25]. The ARISTOTLE study is similar to the AVER-
ROES study already mentioned above. Apixaban was
used at a dose of 5 mg twice daily. As with other oral
antithrombotics, the comparator was warfarin and more
than 18,000 patients were included. Definitive data have
not yet been published.
The efficacy/safety ratio of apixaban was recently pub-
lished in the APPRAISE-2 study, in a different popula-
tion and added to antiplatelet therapy [26]. APPRAISE-2
trial included patients who were at high risk following
acute coronary syndrome. Patients were on antiplatelet
therapy and were randomized to either placebo or two
5-mg daily doses of apixaban. After enrolling 7392
patients trial was stopped because data showed an
increase of intracranial and fatal bleeding events in the
apixaban group than the placebo group and the primary
end point of cardiovascular death, MI, or ischemic
stroke were similar in both groups. Could control of
anticoagulant effect of apixaban leads to a positive bal-
ance in efficacy/safety?
Are there differences between the new drugs and their
efficacy/safety ratios that gives one an advantage over
the others? Taking into account data from the studies
mentioned so far, there were differences in patients
enrolled in the RE-LY [18], Rocket-AF [23] and ARIS-
TOTLE [25] studies. Patients in the ARISTOTLE study
accounted for a large population at risk, from CHADS2
risk score 1 to the highest risk scores. In the RE-LY
study the risk score according to CHADS2 was moder-
ate to mild (32% of patients at risk CHADS2 = 3-6) and
the Rocket-AF study included patients with moderate to
severe risk (87% of patients at risk CHADS = 3-6)
which will make comparisons difficult, even when defi-
nitive data are available.
Other oral antithrombotic drugs on which no data are
available yet are Edox (Daiichi-Sankyo), TAK-442
(Takeda), Betrix (Portola/Merck), and Darex (Astellas),
all of which have been developed for the prevention and
treatment of deep vein thrombosis.
Adverse effects
As mentioned earlier in this article, we consider as axio-
matic that a drug that improves efficiency will poten-
tially be accompanied by an increase in bleeding (the
golden rule). The studies generally show that increased
prevention is accompanied by an increase in major or
minor bleeding complications. The careful choice of
Table 4 Outcomes with dabigatran compared with warfarin
End points Dabigatran 110 mg
×2
Dabigatran 150 mg
×2
Warfarin NNT/NNH: dabigatran 110
mg
NNT/NNH: dabigatran 150
mg
Primary outcomes (%) 1.53 1.11 1.69 625 172
Myocardial infarction
(%)
0.7 0.7 0.5 500 500
Mortality (%) 3.8 3.6 4.1 330 200
Major bleeding (%) 2.7 3.1 3.4 143 333
Intracranial bleeding
(%)
0.2 0.3 0.7 200 250
Net clinical benefits
(%)
7.1 6.9 7.6 200 143
NNH, number needed to harm; NNT, number needed to treat. Net clinical benefits: vascular events, death and major bleeding. Data from the RE-LY trial [16].
Table 5 Rocket-AF study: primary ischemic outcomes
Outcomes Rivaroxaban Warfarin P NNT
Primary outcomes
(noninferiority)
a
1.71 2.16 <0.001 222
Primary outcomes (on
treatment)
1.70 2.15 0.015 222
Non-central nervous system
embolism
0.04 0.19 0.003 667
Vascular death, stroke,
embolism
3.11 3.63 0.034 192
Ischemic stroke 1.34 1.42 0.581 1250
Unknown cause 0.06 0.10 0.366 2500
NNT, number needed to treat. Data from Mahaffey KW. AHA Scientific
Sessions 2010.
aStroke and extracranial embolism, event rate per 100 patients/year.
Table 6 Rocket-AF study: primary safety outcomes
Outcomes Rivaroxaban Warfarin P NNT/
NNH
Major and non-major
clinically relevant
14.91 14.52 0.442 333
≥2 g/dL Hb drop 3.60 3.45 0.576 667
Transfusion (>2 U) 2.77 2.26 0.019 196
Critical organ bleeding 0.82 1.18 0.007 278
Bleeding causing death 0.24 0.48 0.003 417
Hemorrhagic stroke 0.26 0.44 0.024 556
Intracranial hemorrhage 0.49 0.74 0.019 400
NNH, number needed to harm; NNT, number needed to treat. Data from
Mahaffey KW. AHA Scientific Sessions 2010.
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BLED score [27] can help in the selection. When a
laboratory assay is established to determine the degree
of anticoagulation as well as the therapeutic range of
any new drug, it is likely that direction can be adjusted
to raise its profile and then advise warfarin replacement.
In the RE-LY study, patients had more dyspepsia
probably caused by the low pH of the medication. This
resulted in increased drug discontinuation compared
with warfarin.
Another side effect is the increased risk of myocardial
infarction. This paradoxical effect, seen very marginally
in the RE-LY study, has already been reported in
REEDEM [20], a phase II study on patients with acute
coronary syndrome and also noted with the use of a
related drug, ximelagatran. This may be due to the
pharmacology of dabigatran (level of inhibition of
thrombin) or just because there are studies showing that
warfarin protects patients from myocardial infarction.
The possibility of myocardial infarction does not seem
to occur with the use of rivaroxaban but ongoing studies
are required to demonstrate its efficacy in the preven-
tion of acute coronary syndromes [28].
Before use of these drugs, renal function should be
established and monitored because in the presence of
renal function impairment, the dosage of dabigatran
must be adjusted or stopped.
Disadvantages of dabigatran (some are also
applicable to rivaroxaban and apixaban)
1. The administration of two doses daily, which favors
forgetfulness by the patient.
2. Forgetting more than one dose can put the patient
at a prothrombotic risk.
3. Gastric intolerance leading to stopping the
medication.
4. The possibility, although low, of myocardial
infarction.
5. There is no antidote to neutralize the action of the
dabigatran in cases of bleeding or when acute surgical
intervention is necessary.
6. The anticoagulant effect must be controlled and
there is no test to assess the effect or levels of therapeu-
tic range.
7. Caution is advised in the case of impaired renal
function. Dosing should be reduced in renal failure or
the medication discontinued. Nevertheless there are no
studies that clearly indicate the dose to use in these
circumstances.
8. In phase III studies, patients have shown a small
increase in hemorrhages; data related to this risk must
be corroborated in phase IV.
9. The instability of the drug once the packaging is
opened.
10. There are some drug interactions that must be
known (see Table 6).
11. As for other anticoagulants, age is an additional
risk factor for hemorrhages.
12. It is difficult to validate patient compliance.
13. How anticoagulant bridging can be done before
surgery has not yet been established.
14. Cost.
Points 5-8 and 10-14 also apply to rivaroxaban and
apixaban. Rivaroxaban should be used with caution in
patients with severe impaired renal function. Apixaban
excretion is partly dependent on renal function,
although the impact of renal insufficiency has not been
determined.
Advantages of dabigatran, rivaroxaban and
apixaban
1. Fixed dose.
2. No laboratory control (strong arguable).
3. Few drug interactions.
4. No food interactions.
Drawbacks of warfarin
1. Warfarin requires frequent monitoring to maintain
the INR between 2.0 and 3.0 and this is achieved, at
best, in only 55-60% of patients.
2. The therapeutic window is narrow.
3. Its onset of action is slow and, according to the
basal values of vitamin K factors, between 3 and 6 days
are needed to reach therapeutic levels.
4. There are many interactions with medications and
meals.
5. Polymorphisms exist that could determine increased
sensitivity or resistance to warfarin.
6. The suspension of the medication before a surgical
procedure is difficult.
7. Warfarin has a very long half-life.
8. Prothrombin time with INR determination is the
best method available to control therapy but is not good
enough.
9. Specialized centers are required for its control.
10. Age is an additional factor in the risk of bleeding.
Advantages of warfarin
1. Well-established efficacy.
2. Adequate efficacy/safety ratio.
3. Its effect can be reversed by vitamin K.
4. Very low cost.
5. No side effects.
Conclusions
Warfarin has many disadvantages as an anticoagulant
with a long history of benefits. There is no doubt that
new drugs must be found to replace warfarin. The new
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approval or further research offer some benefits but still
cannot replace warfarin until phase IV results show a
proper balance between effectiveness and safety, and
cost/benefit.
Should patients who are on oral anticoagulation with
warfarin be switched to the new oral antithrombotics?.
The answer depends, as indicated in the text, on the
conditions under which the anticoagulant effect of the
new drugs can be controlled and after determining their
therapeutic levels. Nevertheless, if patients are stable
within a therapeutic INR, they should remain on
warfarin.
The combined use of dual antiplatelet therapy with
warfarin is mandatory in certain thrombotic risk situa-
tions. In patients with AF, warfarin, aspirin, and clopido-
grel are associated with more than 3-fold increased risk
of nonfatal and fatal bleeding [29] and this will probably
also apply with the new drugs, both new anticoagulants
and new antiplatelet drugs. These strategies determine
the potential increase in severe or moderate hemorrha-
gic events and even life compromise. There are insuffi-
cient studies to recommend strategies on this point
[29-31]. Proton pump inhibitors could probably help in
preventing gastric hemorrhage [32].
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